A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable locally advanced or metastatic breast cancer

Study identification

• EU PAS number:
  EUPAS23079
• Study ID:
  25870
• Official title and acronym:
  A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2-positive unresectable locally advanced or metastatic breast cancer
• DARWIN EU® study:
  No
• Study countries:
  Cyprus

  Greece
• Study description:
  This observational disease registry is a prospective, multicentre non-interventional study designed to observe clinical outcomes, patient-reported outcomes (PROs), QoL and health economics across anti-cancer treatment regimens and sequences during the course of HER2-positive unresectable locally advanced (LA)/metastatic breast cancer (mBC).
• Study status:
  Finalised

Study timelines

Date when funding contract was signed

Planned:27/04/2015

Actual:27/04/2015

Study start date

Planned:12/10/2016

Actual:12/10/2016

Data analysis start date

Planned:12/10/2016

Actual:12/10/2016

Date of final study report

Planned:30/11/2024

Actual:25/11/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Roche

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ML28801